Drugs / Ensatinib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05186506 | Jan 2022 → Dec 2025 overdue | non-small cell lung carcinoma | Sichuan University | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ensatinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05186506 ↗ |
| Route | Oral | “225 mg administered once daily orally for two years.” NCT05186506 ↗ |